bioMerieux Reports Strong H1 2024 Growth
Company Announcements

bioMerieux Reports Strong H1 2024 Growth

bioMerieux (FR:BIM) has released an update.

bioMerieux, a leader in in vitro diagnostics, reported a robust first-half of 2024 with a 9.9% organic sales growth to €1,902 million, and a significant 33% increase in net income compared to the previous year. The company’s strategic GO•28 plan and recent FDA approvals have propelled the growth, leading bioMerieux to raise its full-year guidance for both sales and CEBIT. The positive financial performance was partly offset by a negative currency impact.

For further insights into FR:BIM stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks European Auto-Generated NewsdeskbioMérieux’s Strong Growth Continues in 2024
TipRanks European Auto-Generated NewsdeskbioMerieux Launches New Vitamin B12 Test
TipRanks European Auto-Generated NewsdeskbioMérieux Reports Voting Rights and Shares
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App